Roche lays foundation stone of new IT innovation centre in Kaiseraugst
Basel, 01 July 2015
290 million Swiss francs being invested in IT building
Today, at Kaiseraugst, Roche laid the foundation stone of a new IT innovation centre, thereby initiating Kaiseraugst's development into one of the Group's largest IT sites worldwide and one of its four IT innovation hubs. Innovative workspaces and state-of-the-art IT infrastructure await the approximately 1,300 employees who will be working in the four new office buildings. Construction will take place in two phases, each comprising two buildings.The first two buildings will be ready for occupation at the end of 2016, while the two others should be occupied by Autumn of 2017. Approximately 290 million Swiss francs are being invested in the buildings.
"The money we are investing at Kaiseraugst is a clear expression of our commitment to the region and underscores the global strategic importance of the IT services within the Group," said Jürg Erismann, Head of the Basel/Kaiseraugst Site. "By strengthening its IT site and amalgamating its IT departments at Kaiseraugst, Roche aims to become a preferred employer for IT specialists."
Bringing global IT functions together at Kaiseraugst
Since IT plays a crucial role in facilitating innovation in medicines development and diagnostics, amalgamating its global IT functions at Kaiseraugst is a hugely significant step for Roche. State-of-the-art infrastructure will enable the approximately 1,300 people who will be working in the new buildings to do their jobs more efficiently in a more team-centred environment with short lines of communication. Until now, these people have been scattered across different locations in Basel and Kaiseraugst.
The construction plans underscore the major significance Roche attaches to sustainability and the associated need for energy efficiency by giving maximum priority to these considerations.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.